Research programme: cytokine receptor antagonists - Trillium Therapeutics

Drug Profile

Research programme: cytokine receptor antagonists - Trillium Therapeutics

Alternative Names: Cytokine receptor antagonists research programme - Trillium Therapeutics

Latest Information Update: 12 Feb 2013

Price : $50

At a glance

  • Originator St. Justine Hospital; University of Montreal
  • Developer Trillium Therapeutics
  • Class
  • Mechanism of Action Cytokine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 12 Feb 2013 Discontinued - Preclinical for Inflammation in Canada (unspecified route)
  • 29 May 2007 No development reported - Preclinical for Inflammation in Canada (unspecified route)
  • 17 Jun 2004 Preclinical trials in Inflammation in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top